Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.
Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in patients with hematologic malignancies. The reported incidence of IPA in the context of chronic obstructive pulmonary disease (COPD) seems to increase. Approximately 1%-2% of overall fatal cases of IPA occur in COPD patients. The combination of factors such as lung immune imbalance, long-term corticosteroid use, increasing rate of bacterial exacerbations over time, and malnutrition are responsible for the emergence of IPA in these patients. The diagnosis of IPA is difficult to establish, which explains the delay in implementing accurate antifungal therapy and the high mortality rate. Persistent pneumonia nonresponsive to appropriate antibiotic treatment raises the concern of an invasive fungal infection. Definite diagnosis is obtained from tissue biopsy evidencing Aspergillus spp. on microscopic examination or in culture. Culture and microscopy of respiratory tract samples have a sensitivity and specificity of around 50%. Other diagnostic tools can be useful in documenting IPA: computed tomography (CT) scan, nonculture-based tests in serum and/or in bronchoalveolar lavage such as antibody/antigen tests for Aspergillus spp. More recent tools such as polymerase chain reaction or [1-->3]-beta-D-glucan have predictive values that need to be further investigated in COPD patients. Antifungal monotherapy using azole voriconazole is recommended as a first-line treatment of IPA. This review assesses the use of voriconazole in COPD patients.
Ader
Florence
F
Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Hôpital de La Croix-Rousse, Lyon, France. florence.ader@univ-lyon1.fr
Bienvenu
Anne-Lise
AL
Rammaert
Blandine
B
Nseir
Saad
S
D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000503:physiopathology; D011237:Predictive Value of Tests; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications* / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole
J Clin Invest. 1985 Nov;76(5):1755-64
3932471
Med Mycol. 2005 May;43 Suppl 1:S147-54
16110807
J Clin Microbiol. 2007 Jun;45(6):1759-65
17428933
Clin Infect Dis. 2006 Feb 15;42(4):479-86
16421791
Am J Med. 1996 Feb;100(2):171-8
8629651
Mycoses. 2002 Oct;45(8):287-94
12572717
J Clin Microbiol. 2003 Aug;41(8):3922-5
12904419
Clin Infect Dis. 2005 Sep 1;41(5):654-9
16080087
Clin Infect Dis. 2005 Jun 15;40(12):1762-9
15909264
Clin Infect Dis. 1998 Jun;26(6):1473-5
9636889
Eur J Intern Med. 2003 Oct;14(6):380-382
14769498
J Clin Microbiol. 2004 Dec;42(12):5517-22
15583275
Clin Infect Dis. 2006 May 15;42(10):1417-27
16619154
J Chemother. 2003 Feb;15(1):71-5
12678418
Chron Respir Dis. 2008;5(1):19-27
18303098
Clin Infect Dis. 2008 Jul 1;47(1):e7-e10
18491963
Cancer. 2002 Feb 15;94(4):1032-6
11920473
J Clin Microbiol. 1999 Dec;37(12):3865-71
10565898
Br J Haematol. 2002 Mar;116(4):803-11
11886384
Clin Pharmacol Ther. 1995 Jun;57(6):662-9
7781266
J Clin Microbiol. 2005 May;43(5):2075-9
15872225
Antimicrob Agents Chemother. 2008 Nov;52(11):4130-6
18710910
Clin Microbiol Infect. 2005 Jun;11(6):427-9
15882191
Clin Infect Dis. 2004 Oct 15;39(8):1241-4
15486850
N Engl J Med. 2002 Aug 8;347(6):408-15
12167683
Clin Microbiol Infect. 2003 Dec;9(12):1224-7
14686988
Eur Respir J. 2007 Oct;30(4):782-800
17906086
Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5
15229094
Med Mycol. 2006 Sep 1;44(Supplement_1):S71-S76
30408937
Clin Infect Dis. 2003 Apr 15;36(8):1087-8
12684928
Clin Microbiol Infect. 2001;7 Suppl 2:54-61
11525219
Br J Radiol. 2005 Aug;78(932):697-703
16046420
Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55
17507545
Chest. 2002 Apr;121(4):1171-6
11948049
J Clin Microbiol. 1995 May;33(5):1164-8
7615723
Medicine (Baltimore). 1998 May;77(3):188-94
9653430
Lancet Infect Dis. 2009 Feb;9(2):89-96
19179225
J Antimicrob Chemother. 2000 May;45(5):673-6
10797091
Clin Infect Dis. 2008 Feb 1;46(3):327-60
18177225
Bone Marrow Transplant. 2000 Apr;25(8):867-71
10808208
Chemotherapy. 2009;55(2):105-13
19151551
Clin Infect Dis. 2001 Feb 1;32(3):358-66
11170942
Radiology. 1998 Sep;208(3):777-82
9722859
Eur Respir J. 2000 Feb;15(2):407-11
10706512
Clin Infect Dis. 2001 Dec 1;33(11):1824-33
11692293
Microbiology (Reading). 1994 Sep;140 ( Pt 9):2475-9
7952197
Am J Clin Pathol. 1986 Oct;86(4):518-23
2429543
J Hosp Infect. 2004 Apr;56(4):269-76
15066736
N Engl J Med. 2003 Dec 11;349(24):2366-7
14668472
Clin Infect Dis. 2004 Mar 15;38(6):913-6
14999640
J Antimicrob Chemother. 2003 Sep;52(3):428-34
12917249
Respir Med. 1992 May;86(3):243-8
1620912
Clin Infect Dis. 2002 Sep 1;35(5):e54-6
12173150
Br J Radiol. 2005 Sep;78(933):862-5
16110114
J Clin Microbiol. 2002 Apr;40(4):1567-8
11923400
Radiology. 2004 Jan;230(1):109-10
14695389
Blood. 2001 Mar 15;97(6):1604-10
11238098
Clin Infect Dis. 2008 Jan 15;46(2):201-11
18171251
J Clin Oncol. 2001 Jan 1;19(1):253-9
11134220
Clin Infect Dis. 2004 Oct 15;39(8):1245-6
15486851
Intensive Care Med. 2003 Nov;29(11):2068-71
12768234
Am J Med. 1986 Aug;81(2):249-54
3090879
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S265-80
12975754
Clin Infect Dis. 2007 Jul 15;45(2):205-16
17578780
Semin Respir Crit Care Med. 2008 Apr;29(2):198-210
18366001
Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S157-87
12975751
Antimicrob Agents Chemother. 2000 Oct;44(10):2865-8
10991875
Am J Respir Crit Care Med. 1999 Dec;160(6):1856-61
10588597
Mycoses. 2001 Nov;44(9-10):356-60
11766098
Eur J Radiol. 1992 Jan-Feb;14(1):37-40
1563402
Int J Antimicrob Agents. 2006 Apr;27(4):274-84
16563707
Drugs. 2004;64(18):1997-2020
15341494
Medicine (Baltimore). 2000 Jul;79(4):250-60
10941354
Clin Diagn Lab Immunol. 2003 Sep;10(5):882-5
12965921
J Med Microbiol. 2003 Nov;52(Pt 11):1031-1032
14532351
Clin Infect Dis. 2007 Feb 15;44(4):531-40
17243056
Radiol Clin North Am. 2001 Nov;39(6):1115-35
11699664
Mycoses. 1997 Dec;40(9-10):353-7
9470421
J Infect Dis. 1983 Jan;147(1):160
6822752
Nat Rev Immunol. 2004 Jan;4(1):1-23
14661066
Clin Infect Dis. 2008 Jan 15;46(2):212-4
18171252
Am J Respir Crit Care Med. 2008 Jan 1;177(1):27-34
17885264
Mayo Clin Proc. 2000 Jun;75(6):562-7
10852416
Clin Infect Dis. 2008 Jun 15;46(12):1813-21
18462102
Lancet Infect Dis. 2005 Oct;5(10):609-22
16183515